{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=116",
    "query": {
      "condition": "Advanced Malignancy",
      "page": 116
    },
    "page_size": 10
  },
  "pagination": {
    "page": 116,
    "page_size": 10,
    "total_count": 9821,
    "total_pages": 983,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=117&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=115&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T18:53:36.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06074588",
      "title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 556,
      "start_date": "2023-11-12",
      "completion_date": "2030-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06074588"
    },
    {
      "nct_id": "NCT07361562",
      "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor, Adult",
        "ERBB2 Altered Breast Cancer",
        "ERBB2 Gene Amplification",
        "HER2 Overexpression",
        "Non-Small Cell Lung Cancer",
        "HER2"
      ],
      "interventions": [
        {
          "name": "CGT4255",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-12-30",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 15,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07361562"
    },
    {
      "nct_id": "NCT01721746",
      "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "BMS-936558",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2012-12-21",
      "completion_date": "2020-12-29",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francciso",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721746"
    },
    {
      "nct_id": "NCT04844073",
      "title": "A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Cancer of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TAK-186",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2021-03-08",
      "completion_date": "2025-06-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 15,
      "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04844073"
    },
    {
      "nct_id": "NCT07246954",
      "title": "A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spiritual Care",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Peace Intervention",
          "type": "OTHER"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-22",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07246954"
    },
    {
      "nct_id": "NCT06022029",
      "title": "A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Mantle Cell Lymphoma",
        "Bladder Cancer",
        "Uveal Melanoma, Recurrent",
        "Cervix Cancer",
        "Carcinoma in Situ",
        "Head and Neck Squamous Cell Carcinoma",
        "Skin Cancer",
        "Metastatic Cancer",
        "Tumor, Solid",
        "Tumor Recurrence"
      ],
      "interventions": [
        {
          "name": "ONM-501",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoNano Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-10-13",
      "completion_date": "2026-08-29",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06022029"
    },
    {
      "nct_id": "NCT04879329",
      "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "disitamab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2022-05-03",
      "completion_date": "2029-04-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 158,
      "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Baldwin Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04879329"
    },
    {
      "nct_id": "NCT03746431",
      "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "HER2-negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Adrenocortical Carcinoma",
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "[111In]-FPI-1547 Injection",
          "type": "DRUG"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection multi-dose",
          "type": "DRUG"
        },
        {
          "name": "FPI-1175 Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection single-dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fusion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-01-17",
      "completion_date": "2025-12-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03746431"
    },
    {
      "nct_id": "NCT00509002",
      "title": "Iressa Study in Patients With Salivary Gland Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "Gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 37,
      "start_date": "2004-05",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509002"
    },
    {
      "nct_id": "NCT06772623",
      "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Carcinoma",
        "c-MET"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2025-03-06",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-13T18:53:36.753Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06772623"
    }
  ]
}